Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1157273

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1157273

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User(Pharma, CROS, CMOs) -Global Forecast -2027

PUBLISHED:
PAGES: 297 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.

"The primers segment will grow at the highest rate in the synthesized oligos market, by product"

By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.

"By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021"

The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

"Asia Pacific region will register a highest CAGR in the oligonucleotide synthesis market"

The market for oligonucleotide synthesis in Asia Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80% and Demand Side - 20%
  • By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
  • By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • LGC Limited (UK)
  • Maravai Life Sciences (US)
  • Agilent Technologies, Inc. (US)
  • Eurofins Scientific (Germany)
  • Kaneka Corporation (Japan)
  • Biolegio B.V. (Netherlands)
  • Biolytic Lab Performance Inc. (US)
  • Microsynth AG (Switzerland)
  • ATDBio Ltd. (UK)
  • Twist Bioscience Corporation (US)
  • Eton Bioscience, Inc. (US)
  • CSBIO (US)
  • Tag Copenhagen A/S (Denmark)
  • Generi Biotech (Czech Republic)
  • Biocomma Limited (China)
  • Hongene Biotech Corporation (China)
  • Hangzhou pharm &chem Co., Ltd (China)
  • Tokyo Chemical Industry Co., Ltd. (Japan)
  • Biogen Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Ionis Pharmaceuticals, Inc. (US)
  • Alnylam Pharmaceuticals, Inc. (US)

Research Coverage:

This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market's size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

Product Code: BT 2680

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET)
    • FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET)
    • FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION)
    • FIGURE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: FINAL CAGR PROJECTIONS (2022-2027)
    • FIGURE 7 OLIGONUCLEOTIDE SYNTHES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.3 DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS

  • 4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
    • FIGURE 15 INCREASING USE OF SYNTHETIC OLIGOS TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2021)
    • FIGURE 16 THERAPEUTIC APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
  • 4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
    • FIGURE 17 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2027
  • 4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2022
    • FIGURE 18 THERAPEUTIC APPLICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
  • 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of synthesized oligos in therapeutic applications
    • TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES
    • FIGURE 21 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS
      • 5.2.1.2 Increasing government investments in synthetic biology and genome projects
      • 5.2.1.3 Growing focus on personalized medicine
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complexities associated with therapeutic oligos
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing R&D investments by key players in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Delivery of oligonucleotide drugs to specific targets
  • 5.3 RANGES/SCENARIOS
    • FIGURE 22 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
    • 5.5.1 KEY INFLUENCERS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 25 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 26 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 TECHNOLOGICAL ANALYSIS
    • 5.8.1 SOLID-PHASE SYNTHESIS
    • 5.8.2 LIQUID-PHASE SYNTHESIS
  • 5.9 INDICATIVE PRICING MODEL ANALYSIS
    • TABLE 2 PRICING ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
  • 5.10 TRADE DATA
    • TABLE 3 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016-2020 (USD THOUSAND)
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS
    • 5.11.2 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS: GOOD MANUFACTURING PRACTICES (GMP)
    • 5.11.3 ISO 13485
    • 5.11.4 IVD & ASR
  • 5.12 PATENT ANALYSIS
    • FIGURE 27 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012-OCTOBER 2022)
    • TABLE 4 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 DEGREE OF COMPETITION
    • 5.13.2 BARGAINING POWER OF SUPPLIERS
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 THREAT OF NEW ENTRANTS
  • 5.14 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
  • 5.16 KEY BUYING CRITERIA BY END USERS
    • FIGURE 29 BUYING CRITERIA OF END USERS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 8 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 12 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.2 OLIGONUCLEOTIDE-BASED DRUGS
    • 6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED MARKET IN 2021
    • TABLE 13 OLIGONUCLEOTIDE-BASED THERAPIES
    • TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 15 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 18 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 SYNTHESIZED OLIGONUCLEOTIDES
    • TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    • TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
      • 6.3.1.1 Primers
        • 6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics to drive segment
    • TABLE 25 PRIMERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 26 PRIMERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 PRIMERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 PRIMERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 29 PRIMERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.3.1.2 Probes
        • 6.3.1.2.1 Probes to detect various infectious agents and altered DNA/RNA sequences
    • TABLE 30 PROBES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 31 PROBES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 PROBES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 PROBES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 PROBES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.3.1.3 DNA oligos
        • 6.3.1.3.1 Innovations in DNA oligos to eliminate time-consuming PCR and drive segment
    • TABLE 35 DNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 36 DNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 DNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 DNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 39 DNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.3.1.4 RNA oligos
        • 6.3.1.4.1 RNA oligos to be used as molecular diagnostic tools
    • TABLE 40 RNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 41 RNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 RNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 43 RNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 RNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.3.1.5 Other synthesized oligonucleotides
    • TABLE 45 OTHER SYNTHESIZED OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 46 OTHER SYNTHESIZED OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 47 OTHER SYNTHESIZED OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 OTHER SYNTHESIZED OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 OTHER SYNTHESIZED OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    • TABLE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
      • 6.3.2.1 Custom oligonucleotides
        • 6.3.2.1.1 Surge in demand in clinical and preclinical studies to propel segment
    • TABLE 51 CUSTOM OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 52 CUSTOM OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 CUSTOM OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 CUSTOM OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 55 CUSTOM OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.3.2.2 Predesigned oligos
        • 6.3.2.2.1 Predesigned oligos to be used in routine research applications, such as PCR and sequencing
    • TABLE 56 PREDESIGNED OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 57 PREDESIGNED OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 PREDESIGNED OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 PREDESIGNED OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 PREDESIGNED OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.4 REAGENTS
    • 6.4.1 GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO PROPEL MARKET
    • TABLE 61 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 EQUIPMENT
    • 6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO STIMULATE MARKET
    • TABLE 66 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 67 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 68 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020-2027 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 72 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 73 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 74 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 75 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 77 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.2 THERAPEUTIC APPLICATIONS
    • TABLE 78 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 80 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE
    • TABLE 83 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
      • 7.2.1.1 Antisense oligonucleotide-based therapies
        • 7.2.1.1.1 Antisense oligos to form basis of therapies in clinical trials
    • TABLE 84 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 85 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 86 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 87 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 88 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.1.2 siRNA oligonucleotide-based therapies
        • 7.2.1.2.1 Ease of drug target identification with bioinformatics to boost segment
    • TABLE 89 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 90 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 91 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 92 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 93 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.1.3 CpG oligonucleotide-based therapies
        • 7.2.1.3.1 CpG ODNs to show significant potential for variety of disease treatments, including cancer
    • TABLE 94 CPG OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 95 CPG OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 96 CPG OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 97 CPG OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 98 CPG OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.2 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    • TABLE 99 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
      • 7.2.2.1 Neurological disorders
        • 7.2.2.1.1 Neurological disorders dominated market by disease type in 2020
    • TABLE 100 NEUROLOGICAL DISORDERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 101 NEUROLOGICAL DISORDERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 102 NEUROLOGICAL DISORDERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 103 NEUROLOGICAL DISORDERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 104 NEUROLOGICAL DISORDERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.2.2 Infectious diseases
        • 7.2.2.2.1 Antisense therapies and oligonucleotide aptamers to be significant in treatment and diagnosis of infectious diseases
    • TABLE 105 INFECTIOUS DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 106 INFECTIOUS DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 107 INFECTIOUS DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 108 INFECTIOUS DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 109 INFECTIOUS DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.2.3 Other diseases
    • TABLE 110 OTHER DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 111 OTHER DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 112 OTHER DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 113 OTHER DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 114 OTHER DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 RESEARCH APPLICATIONS
    • TABLE 115 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 117 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 118 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 119 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 120 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.1 PCR
      • 7.3.1.1 Increasing use of PCR in research to drive market
    • TABLE 121 PCR: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 122 PCR: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 123 PCR: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 124 PCR: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 125 PCR: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.2 SEQUENCING
      • 7.3.2.1 Advancements in technologies and low cost of DNA sequencing to boost segment
    • TABLE 126 SEQUENCING: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 127 SEQUENCING: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 128 SEQUENCING: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 129 SEQUENCING: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 130 SEQUENCING: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.3 OTHER RESEARCH APPLICATIONS
    • TABLE 131 OTHER RESEARCH APPLICATIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 132 OTHER RESEARCH APPLICATIONS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 133 OTHER RESEARCH APPLICATIONS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 134 OTHER RESEARCH APPLICATIONS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 135 OTHER RESEARCH APPLICATIONS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 DIAGNOSTIC APPLICATIONS
    • 7.4.1 GROWING FIELDS OF MOLECULAR DIAGNOSTICS (MDX) AND IN VITRO DIAGNOSTICS (IVD) TO AUGMENT SEGMENT
    • TABLE 136 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 137 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 138 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 139 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 140 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 141 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 142 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 143 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 144 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 146 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.2 HOSPITALS
    • 8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS TO STIMULATE MARKET
    • TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY AND THERAPEUTICS TO DRIVE SEGMENT
    • TABLE 152 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 153 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 154 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 156 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 DIAGNOSTIC LABORATORIES
    • 8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO STIMULATE GROWTH
    • TABLE 157 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 158 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 159 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 161 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
    • 8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO AID GROWTH
    • TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 ACADEMIC RESEARCH & INSTITUTES
    • 8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS TO USE OLIGOS FOR GENOMIC TECHNOLOGIES
    • TABLE 167 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 168 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 169 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 171 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 172 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT
    • TABLE 173 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 174 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 175 NORTH AMERICA: SYNTHESIZES OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 176 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 178 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 179 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 180 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 181 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Government initiatives and strategic developments to drive market
    • TABLE 182 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 183 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 184 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 185 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 186 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 187 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 188 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 189 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Strong research infrastructure and availability of funding to support market
    • TABLE 190 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 191 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 192 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 193 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 194 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 195 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 196 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 197 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 198 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 199 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 201 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 202 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 203 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 204 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 205 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 206 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.1 UK
      • 9.3.1.1 Increasing strategic developments by market players to propel market
    • TABLE 207 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 208 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 209 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 210 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 211 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 212 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 213 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 214 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.2 GERMANY
      • 9.3.2.1 Presence of several academic & research institutes to aid growth
    • TABLE 215 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 216 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 217 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 218 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 219 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 220 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 221 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 222 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Government initiatives to strengthen R&D activities and drive market
    • TABLE 223 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 224 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 225 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 226 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 227 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 228 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 229 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 230 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Increasing research activities in life sciences to boost market
    • TABLE 231 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 232 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 233 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 234 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 235 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 236 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 237 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 238 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Government initiatives for development of biomedicine and healthcare sectors to stimulate market
    • TABLE 239 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 240 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 241 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 242 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 243 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 244 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 245 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 246 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 247 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 248 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 249 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 250 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 251 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 252 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 253 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 254 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: MARKET SNAPSHOT
    • TABLE 255 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 256 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 257 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 258 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 259 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 260 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 262 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 263 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Increasing focus of Chinese biopharma companies to aid market
    • TABLE 264 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 265 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 266 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 267 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 268 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 269 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 270 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 271 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Increasing awareness of oligos through conferences and workshops to drive market
    • TABLE 272 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 273 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 274 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 275 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 276 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 277 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 278 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 279 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Strong initiatives to develop bio clusters and increased adoption of genomic technologies to aid market
    • TABLE 280 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 281 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 282 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 283 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 284 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 285 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 286 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 287 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 288 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 289 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 290 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 291 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 292 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 293 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 294 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 295 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.5 LATIN AMERICA
    • TABLE 296 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 297 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 298 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 299 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 300 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 301 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 302 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 303 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 304 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.5.1 BRAZIL
      • 9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market
    • TABLE 305 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 306 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 307 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 308 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 309 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 310 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 311 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 312 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.5.2 MEXICO
      • 9.5.2.1 Increasing research in synthetic biology to drive market
    • TABLE 313 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 314 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 315 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 316 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 317 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 318 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 319 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 320 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.5.3 REST OF LATIN AMERICA
    • TABLE 321 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 322 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 323 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 324 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 325 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 326 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 327 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 328 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 GROWING ACCEPTANCE OF PERSONALIZED MEDICINE TO PROPEL MARKET
    • TABLE 329 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 330 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 331 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 332 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 333 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 334 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 335 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 336 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • TABLE 337 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY STRATEGIES ADOPTED
  • 10.3 MARKET SHARE ANALYSIS
    • FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), 2021
    • TABLE 338 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR RESEARCH AND DIAGNOSTIC MARKET): DEGREE OF COMPETITION
    • FIGURE 33 OLIGONUCLEOTIDE SYNTHESIS MARKET: MARKET SHARE ANALYSIS (THERAPEUTIC MARKET), 2021
    • TABLE 339 OLIGONUCLEOTIDE SYNTHESIS MARKET (FOR THERAPEUTICS MARKET): DEGREE OF COMPETITION
  • 10.4 REVENUE ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
    • FIGURE 34 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
  • 10.5 COMPANY EVALUATION MATRIX
    • FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX, 2021
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
  • 10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
    • FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
  • 10.7 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 340 OLIGONUCLEOTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 341 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
  • 10.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 10.8.1 COMPANY FOOTPRINT
    • TABLE 342 COMPANY FOOTPRINT ANALYSIS: KEY PLAYERS
    • 10.8.2 PRODUCT FOOTPRINT
    • TABLE 343 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
    • 10.8.3 APPLICATION FOOTPRINT
    • TABLE 344 APPLICATION FOOTPRINT ANALYSIS: KEY PLAYERS
    • 10.8.4 REGIONAL FOOTPRINT
    • TABLE 345 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
  • 10.9 COMPETITIVE SCENARIO AND TRENDS
    • 10.9.1 PRODUCT LAUNCHES
    • TABLE 346 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES (JANUARY 2019-OCTOBER 2022)
    • 10.9.2 DEALS
    • TABLE 347 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS (JANUARY 2019-OCTOBER 2022)
    • 10.9.3 OTHER DEVELOPMENTS
    • TABLE 348 OLIGONUCLEOTIDE SYNTHESIS MARKET: OTHER DEVELOPMENTS (JANUARY 2019-OCTOBER 2022)

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View)**
    • 11.1.1 DANAHER CORPORATION
    • TABLE 349 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT
    • 11.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 350 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
    • 11.1.3 MERCK KGAA
    • TABLE 351 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
    • 11.1.4 EUROFINS SCIENTIFIC
    • TABLE 352 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
    • 11.1.5 LGC LIMITED
    • TABLE 353 LGC LIMITED: COMPANY OVERVIEW
    • FIGURE 41 LGC LIMITED: COMPANY SNAPSHOT
    • 11.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 354 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
    • 11.1.7 KANEKA CORPORATION
    • TABLE 355 KANEKA CORPORATION: COMPANY OVERVIEW
    • FIGURE 43 KANEKA CORPORATION: COMPANY SNAPSHOT
    • 11.1.8 MARAVAI LIFESCIENCES
    • TABLE 356 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
    • FIGURE 44 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT
    • 11.1.9 BIOLEGIO B.V.
    • TABLE 357 BIOLEGIO B.V.: COMPANY OVERVIEW
    • 11.1.10 BIOLYTIC LAB PERFORMANCE INC.
    • TABLE 358 BIOLYTIC LAB PERFORMANCE INC.: COMPANY OVERVIEW
    • 11.1.11 MICROSYNTH AG
    • TABLE 359 MICROSYNTH AG: COMPANY OVERVIEW
  • 11.2 THERAPEUTIC PLAYERS
    • 11.2.1 BIOGEN INC.
    • TABLE 360 BIOGEN INC.: COMPANY OVERVIEW
    • FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT
    • 11.2.2 SAREPTA THERAPEUTICS, INC.
    • TABLE 361 SAREPTA THERAPEUTICS INC.: COMPANY OVERVIEW
    • FIGURE 46 SAREPTA THERAPEUTICS INC.: COMPANY SNAPSHOT
    • 11.2.3 IONIS PHARMACEUTICALS, INC.
    • TABLE 362 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 47 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
    • 11.2.4 ALNYLAM PHARMACEUTICALS, INC.
    • TABLE 363 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 48 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • * Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
  • 11.3 OTHER PLAYERS
    • 11.3.1 ADTBIO LTD.
    • 11.3.2 TWIST BIOSCIENCE CORPORATION
    • 11.3.3 ETON BIOSCIENCE, INC.
    • 11.3.4 CSBIO
    • 11.3.5 TAG COPENHAGEN A/S
    • 11.3.6 GENERI BIOTECH
    • 11.3.7 BIOCOMMA LIMITED
    • 11.3.8 HONGENE BIOTECH CORPORATION
    • 11.3.9 HANGZHOU PHARM &CHEM CO., LTD.
    • 11.3.10 TOKYO CHEMICAL INDUSTRY CO., LTD. (TCI)

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!